954138-07-9

954138-07-9 structure

Name: PF-03049423 free base
Chemical Name: 3-[4-(2-Hydroxyethyl)-1-piperazinyl]-7-(6-methoxy-3-pyridinyl)-1- (2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one
CAS Number: 954138-07-9
Molecular Formula: C₂₄H₃₂N₆O₄
Molecular Weight: 468.54900
Catalog: Signaling Pathways Metabolic Enzyme/Protease Phosphodiesterase (PDE)
Create Date: 2017-11-22 12:20:32
Modify Date: 2024-01-21 16:28:12
PF-03049423 (Compound PF-5) free base is a potent and highly selective phosphodiesterase-5A inhibitor with an IC50 of about 0.2 nM for rat and human platelet enzyme. PF-03049423 free base can be used for the research of acute ischaemic stroke[1].

Name	3-[4-(2-Hydroxyethyl)-1-piperazinyl]-7-(6-methoxy-3-pyridinyl)-1- (2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one

Description	PF-03049423 (Compound PF-5) free base is a potent and highly selective phosphodiesterase-5A inhibitor with an IC50 of about 0.2 nM for rat and human platelet enzyme. PF-03049423 free base can be used for the research of acute ischaemic stroke[1].
Related Catalog	Signaling Pathways >> Metabolic Enzyme/Protease >> Phosphodiesterase (PDE) Research Areas >> Neurological Disease
Target	PDE5A rat and human platelet enzyme:~0.2 nM (IC50)
In Vivo	PF-03049423 (Compound PF-5) (1-10 mg/kg; s.c.; b.i.d. for 7 days) promotes functional recovery in a rat model of severe stroke induced by permanent middle cerebral artery occlusion[1]. PF-03049423 (1.0 mg/kg b.i.d. or 0.6 mg/kg q.d. for 7 days) improves poststroke sensory–motor behavioral outcome even when the treatment is initiated 24-72 hours after occlusion[1]. Animal Model: Male Sprague-Dawley rats, middle cerebral artery occlusion (MCA-o) model[1] Dosage: 0.1, 1, or 10 mg/kg Administration: Subcutaneous injection, b.i.d. for 7 days Result: Improved functional recovery at 1 mg/kg and 10 mg/kg.